Christophe Schilling founded Genomatica in 1998. Since being named CEO in May 2009, he has led Genomatica to widespread recognition as a leader in industrial biotech, with a commercialized first process and plant and multiple leading partners. The company has earned awards for industry impact (recognized in ICIS Top40 Power Players five years in a row), engineering (Kirkpatrick), science (EPA Presidential Green Chemistry), industry leadership (voted #1 Hottest four years in a row by Biofuels Digest), and company culture (The Scientist as a Best Place to Work). Christophe is Chairman of Biocom, the largest advocate organization for California’s life sciences sector; serves on BIO’s Industrial & Environmental Section Governing Board; serves on the World Economic Forum Global Agenda Council on Biotechnology; and is a member of YPO, an international leadership organization for chief executives. In this exclusive interview with Il Bioeconomista, he talks about the recent agreement with Covestro and the Genomatica’s way towards the bioeconomy.
“Innovation is the key for the transformation towards a bioeconomy, and industrial biotechnology is the driving force and innovation engine for this megatrend”. Jürgen Eck, CEO BRAIN AG, talks with Il Bioeconomista. In this exclusive interview, the Most Innovative Bioeconomy CEO 2018 voted by our readers, talks about his company, the bioeconomy and the concept of innovation.
UK biotech company Ingenza has joined forces with leading universities and industrial partners to participate in the ConBioChem collaboration, a translational project focused on the development of novel platform technologies for the continuous bio-production of commodity chemicals.
Clariant, a Swiss leader in specialty chemicals, and French industrial biotech company Global Bioenergies last Tuesday announced the development of a new bio-based polymer for cosmetic creams and lotions, which is derived from renewable isobutene.
Genomatica published the results of a major survey of sustainability issues in the mainstream chemical industry. The survey was conducted together with ICIS, the world’s largest petrochemical market information provider. The survey, fourth in a series they have conducted since 2009, revealed substantial advances for sustainability and renewable chemicals in general, for chemical producers, users (companies making products from basic and intermediate chemicals) and distributors.
Rome will be the Euro-mediterranean capital of the bioeconomy for a couple of days. The Italian Forum on Industrial Biotechnology and Bioeconomy (IFIB) goes to the Italian capital from 5 to 6 October at the Palazzo Rospigliosi, in front of the House of the President of the Republic.
Global Bioenergies expands in the Netherlands. The French biotech company led by Marc Delcourt signed a contribution agreement with the shareholders of Syngip B.V. to transfer all Syngip shares to Global Bioenergies S.A. The transaction’s completion remains subject to the fulfilment of several suspensive conditions including approval by the shareholders of Global Bioenergies.
“Biotech is becoming increasingly important to the mainstream chemical industry as the demand for more sustainable solutions intensifies. Biotech is especially well-suited to help with some of the industry’s biggest challenges”. To say it – in this exclusive interview with Il Bioeconomista – is Christophe Schilling, founder and CEO of Genomatica, a widely-recognized bioengineering leader for the chemical industry. The San Diego-based biotechnology company develops and licenses bio-based manufacturing processes for the production of intermediate and basic chemicals.
Since being named CEO in May 2009, Christophe Schilling has led Genomatica to widespread recognition as a leader in industrial biotechnology, with a commercialized first process, top-tier licensees, strong investors and an unrivaled string of awards for engineering (Kirkpatrick), science (EPA Presidential Green Chemistry), industry leadership (voted #1 Hottest three years in a row by Biofuels Digest), and company culture (The Scientist as a Best Place to Work). Schilling frequently speaks on industry trends at major conferences and serves as a member of the World Economic Forum Global Agenda Council on Biotechnology.
Danish biotech giant Novozymes last week broke ground for its new innovation campus in Lyngby, close to the Technical University of Denmark and seven kilometers from Novozymes’ headquarters in Bagsværd.
“Scotland has under 10% of the UK population and over 30% of the land mass giving it considerably more capacity for growing biomass as feedstock for the bioeconomy. Scotland has great research capabilities, a strong base of SMEs looking to develop its bio-capabilities and the joined up support of the government with all its agencies in developing this opportunity”. Roger Kilburn, CEO IBioIC (Industrial Biotechnology Innovation Centre) Scotland, talks to Il Bioeconomista. In this long, exclusive interview, he talks about UK and Scottish bioeconomy, the role of industrial biotechnology and Brexit. “The fundamental reasons for developing the bioeconomy – he says – are the positive impact it has on sustainability, the environment and the ability to produce new and improved materials. None of these fundamentals are affected by Brexit”.